Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis-Reference-Cited by-同舟云学术

Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis

Published:2024-04-05 Issue:3 Volume:24 Page:419-431
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Hameed Ishaque,Shah Syeda Ayesha,Aijaz Ashnah,Mushahid Hasan^ORCID,Farhan Syed Husain,Dada Muhammad,Khan Adam Bilal,Amjad Reeha,Alvi Fawad,Murtaza Mustafa,Zuberi Zaid,Hamza Mohammad

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40256-024-00642-8.pdf

Reference34 articles.

1. Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, Gąsior M, Jankowski P, Jóźwiak J, Kłosiewicz-Latoszek L, Kowalska I, Małecki M, Prejbisz A, Rakowski M, Rysz J, Solnica B, Sitkiewicz D, Sygitowicz G, Sypniewska G, Tomasik T, Windak A, Zozulińska-Ziółkiewicz D, Cybulska B. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17:1447–1547. Available at: https://www.archivesofmedicalscience.com/PoLA-CFPiP-PCS-PSLD-PSD-PSH-guidelines-on-diagnosis-and-therapy-of-lipid-disorders,141941,0,2.html. Accessed 8 July 2023.

2. Khan SU, Michos ED. Cardiovascular mortality after intensive LDL-Cholesterol lowering: does baseline LDL-Cholesterol really matter? Am J Prev Cardiol. 2020;1: 100013.

3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493):1267-78. Available at: http://www.thelancet.com/article/S0140673605673941/fulltext. Accessed 8 July 2023.

4. Tan H, Liu L, Zheng Q, Zhang D, Liu Q, Cui D, Gao L, Wang Z, Wang WL, Liu J. Effects of combined lipid-lowering therapy on low-density lipoprotein cholesterol variability and cardiovascular adverse events in patients with acute coronary syndrome. Adv Ther. 2021;38:3389–98.

5. Oh PC, Jang AY, Ha K, Kim M, Moon J, Suh SY, Lee K, Han SH, Kang WC. Effect of atorvastatin (10 mg) and ezetimibe (10 mg) combination compared to atorvastatin (40 mg) alone on coronary atherosclerosis. Am J Cardiol. 2021;154:22–8.